Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Leuk Lymphoma. 2020 Jan 6;61(4):950–954. doi: 10.1080/10428194.2019.1702178

Figure 1. Treatment response and progression-free survival in patients in the primary refractory subgroup.

Figure 1.

Figure 1.

Figure 1.

(A) Change from baseline in target lesion size and (B) duration of response in patients with primary refractory cHL who had ≥1 evaluable postbaseline assessment (n=68). (C) Progression-free survival. CR, complete response; PR, partial response